Cambridge, MA, United States
Cambridge, MA, United States

Time filter

Source Type

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ra Pharmaceuticals, Inc., (NASDAQ:RARX), a clinical stage biopharmaceutical company focusing on the development of next-generation therapeutics for the treatment of complement-mediated diseases, today joins forces with 30 million health care advocates around the world for the 10th annual Rare Disease Day®. Rare Disease Day, which is always the last day of February, is an annual awareness day dedicated to elevating public understanding of rare diseases and calling attention to the special challenges people living with rare diseases face. This year’s focus is on research and the global slogan for 2017 is “With Research, Possibilities are Limitless.” “A decade into its existence, the annual Rare Disease Day has achieved a noteworthy milestone in its efforts calling attention to the public health issues associated with rare diseases, a mission Ra Pharma is proud to support,” said Doug Treco, PhD, President and Chief Executive Officer of Ra Pharma. “As we prepare to initiate two Phase 2 clinical trials of our lead compound RA101495 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and refractory generalized myasthenia gravis (rMG), as well as a Phase 1b clinical trial supporting development in lupus nephritis (LN), we are confident in our ability to address the unmet need for people living with rare diseases where there are limited or no treatment options.” According to the National Institutes of Health (NIH), a disease is rare if it affects fewer than 200,000 people. Nearly 1 in 10 Americans live with a rare disease—affecting 30 million people—and nearly half of these patients are children. There are more than 7,000 rare diseases and only approximately 450 FDA-approved medical treatments. Rare Disease Day takes place every year on the last day of February (February 28 or February 29 in a leap year)—the rarest date on the calendar—to underscore the nature of rare diseases and what patients face. It was established in Europe in 2008 by EURORDIS, the organization representing rare disease patients in Europe, and is now observed in more than 80 nations. Rare Disease Day is sponsored in the U.S. by the National Organization for Rare Disorders (NORD)®, the largest and leading independent, nonprofit organization committed to the identification, treatment, and cure of rare diseases. For more information about Rare Disease Day in the U.S., go to www.rarediseaseday.us. For information about global activities, go to www.rarediseaseday.org. To search for information about rare diseases, visit NORD’s website, www.rarediseases.org. Ra Pharma is developing RA101495 for paroxysmal nocturnal hemoglobinuria (PNH), refractory generalized myasthenia gravis (rMG), and lupus nephritis (LN). The product is designed for convenient, subcutaneous self-administration. RA101495 is a synthetic, macrocyclic peptide discovered using Ra Pharma’s powerful proprietary drug discovery technology. The peptide binds complement C5 with subnanomolar affinity and allosterically inhibits its cleavage into C5a and C5b upon activation of the classical, alternative or lectin pathways. RA101495 also directly binds to C5b, disrupting the interaction between C5b and C6 and preventing assembly of the membrane attack complex (MAC). This activity defines an additional and novel mechanism for the inhibition of C5 function. In Phase 1 studies, dosing of RA101495 was well tolerated in healthy volunteers and demonstrated sustained and near complete suppression of hemolysis and complement activity. Ra Pharma’s proprietary Extreme Diversity™ mRNA display platform allows us to produce synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. The platform generates highly specific and stable peptide-like molecules with the potential for greatly increased bioavailability, improved cell permeability, and the opportunity to address protein-protein interactions including previously undruggable targets. It can produce libraries of 10 to 100 trillion members, allowing for the rapid discovery of highly potent candidate molecules. The platform is being leveraged for our emerging pipeline projects in Factor D and C1. Ra Pharmaceuticals is a clinical stage biopharmaceutical company focusing on the development of next-generation therapeutics for complement-mediated diseases. The Company discovers and develops peptides and small molecules to target key components of the complement cascade. For more information, please visit: www.rapharma.com. This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the safety, efficacy and regulatory and clinical progress of our product candidates, including RA101495. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include the risks that Ra Pharma’s product candidates, including RA101495, will not successfully be developed or commercialized; as well as the other factors discussed in the “Risk Factors” section in Ra Pharma’s most recently filed Quarterly Report on Form 10-Q, as well as other risks detailed in Ra Pharma’s subsequent filings with the Securities and Exchange Commission. There can be no assurance that the actual results or developments anticipated by Ra Pharma will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Ra Pharma. All information in this press release is as of the date of the release, and Ra Pharma undertakes no duty to update this information unless required by law.


News Article | November 1, 2016
Site: www.prnewswire.co.uk

ReportsnReports.com adds "Lupus Nephritis - Pipeline Review, H2 2016" to its store providing comprehensive information on the therapeutics under development for Lupus Nephritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Lupus Nephritis and features dormant and discontinued projects. Complete report on Lupus Nephritis Market Research with 37 market data tables and 15 figures, spread across 142 pages is available at http://www.reportsnreports.com/reports/729119-lupus-nephritis-pipeline-review-h2-2016.html . Companies discussed in this research report include AbbVie Inc, Asahi Kasei Pharma Corp., Astellas Pharma Inc., Aurinia Pharmaceuticals Inc, Azano Pharmaceuticals Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Deltanoid Pharmaceuticals Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, HanAll Biopharma Co., Ltd., Invion Limited, KPI Therapeutics, Inc., MedImmune, LLC, Omeros Corporation, Ra Pharmaceuticals, Inc., Resolve Therapeutics, LLC, Takeda Pharmaceutical Company Limited and TxCell SA. Drug Profiles mentioned in this research are abatacept, anifrolumab, belimumab, BI-655064, BMS-986147, dalazatide, DP-001, Drug to Antagonize Bradykinin Receptor B1 for Lupus Nephritis, ENTX-DN, HL-161, INV-103, ixazomib citrate, mizoribine, Monoclonal Antibody for Lupus Nephritis, obinutuzumab, OMS-721, P-Dex, RA-101495, RO-5461111, RSLV-145, Stem Cell Therapy for Autoimmune Diseases, Synthetic Peptide to Inhibit Complement C5 for Paroxysmal Nocturnal Hemoglobinuria, Atypical Hemolytic Uremic Syndrome and Autoimmune Disorders, venetoclax, voclosporin and Y-175L. Lupus nephritis is inflammation of the kidney that is caused by systemic lupus erythematous (SLE). Also called lupus, SLE is an autoimmune disease. Symptoms include weight gain, high blood pressure, dark urine and foamy, frothy urine. Treatment includes corticosteroids, immunosuppressive drugs and health lifestyle. Lupus Nephritis pipeline therapeutics constitutes close to 25 molecules. Out of which approximately 22 molecules are developed by Companies and remaining by the Universities/Institutes. The molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 5, 4, 7 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively. The research outlays comprehensive information on the therapeutics under development for Lupus Nephritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews of key players involved in therapeutic development for Lupus Nephritis and features dormant and discontinued projects. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Another newly published market research report titled on Schistosomiasis - Pipeline Review, H2 2016 provides comprehensive information on the therapeutic development for Schistosomiasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Schistosomiasis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development are Kancera AB, LondonPharma Ltd, Merck KGaA and Salvensis. Schistosomiasis Pipeline market research report of 39 pages is available at http://www.reportsnreports.com/reports/729129-schistosomiasis-pipeline-review-h2-2016.html . ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports. Connect With Us on: Facebook:https://www.facebook.com/ReportsnReports/ LinkedIn:https://www.linkedin.com/company/reportsnreports Twitter:https: //twitter.com/marketsreports G+ / Google Plus: https://plus.google.com/111656568937629536321/posts RSS/Feeds: http://www.reportsnreports.com/feed/l-latestreports.xml


CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ra Pharmaceuticals, Inc., (NASDAQ:RARX), a clinical stage biopharmaceutical company focusing on the development of next-generation therapeutics for the treatment of complement-mediated diseases, today announced that Doug Treco, PhD, President and Chief Executive Officer, will present at the Cowen and Company 37th Annual Health Care Conference on Tuesday, March 7, 2017 at 11:20 a.m. E.T. The conference is being held at the Boston Marriott Copley Place. The presentation will be webcast live and can be accessed by visiting the investor relations section of the Company’s website, www.rapharma.com. A replay of the presentation will also be available and archived on the site for three weeks. Ra Pharmaceuticals is a clinical stage biopharmaceutical company focusing on the development of next-generation therapeutics for complement-mediated diseases. The Company discovers and develops peptides and small molecules to target key components of the complement cascade. For more information, please visit: www.rapharma.com.


Patent
Ra Pharmaceuticals | Date: 2015-12-08

The present invention provides inhibitors and/or antagonists of plasma kallikrein. Also provided are methods of utilizing the inhibitors as therapeutics.


Patent
Ra Pharmaceuticals | Date: 2013-03-14

The present invention provides inhibitors and/or antagonists of plasma kallikrein. Also provided are methods of utilizing the inhibitors as therapeutics.


News Article | October 27, 2016
Site: www.businesswire.com

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ra Pharmaceuticals, Inc. (“Ra Pharmaceuticals” or “Ra”), a clinical stage biopharmaceutical company focusing on using its proprietary peptide chemistry platform to develop novel therapeutics for the treatment of serious diseases that are caused by excessive or uncontrolled activation of the complement system, a critical component of the immune system, today announced the pricing of its initial public offering of 7,049,230 shares of common stock at a public off


What:   Ra Pharmaceuticals Inc. (Nasdaq:RARX), a clinical stage biopharmaceutical company focusing on the development of next-generation therapeutics for diseases of complement dysregulation, will visit the Nasdaq MarketSite in Times Square in celebration of its initial public offering (IPO). In honor of the occasion, Douglas Treco, Ph.D., Chief Executive Officer and Co-Founder, will ring the Opening Bell. When:  Thursday, October 27, 2016 – 9:15 a.m. to 9:30 a.m. ET Social Media:  For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies, please visit our Facebook page:  http://www.facebook.com/NASDAQ. For photos from ceremonies and events, please visit our Instagram page:  http://instagram.com/nasdaq For livestream of ceremonies and events, please visit our YouTube page:  http://www.youtube.com/nasdaq/live For news tweets, please visit our Twitter page:  http://twitter.com/nasdaq For exciting viral content and ceremony photos, please visit our Tumblr page:  http://nasdaq.tumblr.com/ Webcast: A live stream of the Nasdaq Opening Bell will be available at: https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx Photos: To obtain a hi-resolution photograph of the Market Open, please go to http://business.nasdaq.com/discover/market-bell-ceremonies and click on the market open of your choice. About Ra Pharmaceuticals  Ra Pharmaceuticals is a clinical stage biopharmaceutical company focusing on the development of nextgeneration therapeutics for diseases of complement dysregulation and for orphan indications. The Company utilizes small molecules and peptide approaches to address pathological targets in the complement cascade. Derived from its proprietary Extreme Diversity™ peptide chemistry platform, RA101495 is a macrocyclic peptide inhibitor of complement C5, and is currently in Phase 1 development for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). For more information, please visit: www.rapharma.com. About Nasdaq  Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,700 listed companies with a market value of approximately $9.3 trillion and nearly 18,000 corporate clients. To learn more, visit: nasdaq.com/ambition or business.nasdaq.com.


News Article | November 29, 2016
Site: www.businesswire.com

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ra Pharmaceuticals (NASDAQ:RARX), a clinical stage biopharmaceutical company focusing on the development of next-generation therapeutics for diseases of complement dysregulation, today announced financial results for the three months ended September 30, 2016 and provided an update on recent corporate and clinical developments. “Our successful initial public offering in October strengthened our balance sheet and allows us to initiate our Phase 2 clinical progra


CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ra Pharmaceuticals (NASDAQ:RARX), a clinical stage biopharmaceutical company focusing on the development of next-generation therapeutics for diseases of complement dysregulation, today announced that Doug Treco, PhD, President and Chief Executive Officer, will present at the BMO Capital Markets Prescriptions for Success Healthcare Conference on Wednesday, December 14, 2016 at 2:00 p.m. E.T. The conference is being held at the InterContinental New York Barclay Hotel. The presentation will be webcast live and can be accessed by visiting the investor relations section of the Company’s website, www.rapharma.com. A replay of the presentation will also be available and archived on the site for three weeks. Ra Pharmaceuticals is a clinical stage biopharmaceutical company focusing on the development of next-generation therapeutics for diseases of complement dysregulation and other orphan indications. The Company discovers and develops peptides and small molecules to target key components of the complement cascade. For more information, please visit: www.rapharma.com.


News Article | October 27, 2016
Site: globenewswire.com

NEW YORK, Oct. 27, 2016 (GLOBE NEWSWIRE) -- Ra Pharmaceuticals Inc. (Nasdaq:RARX), a clinical stage biopharmaceutical company focusing on the development of next-generation therapeutics for diseases of complement dysregulation, visited the Nasdaq MarketSite in Times Square today in celebration of  its initial public offering (IPO) on The Nasdaq Stock Market on October 26, 2016. A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/d59a5715-0c97-4d3d-a5e3-bb4d47a6045b Ra Pharmaceuticals uses its proprietary peptide chemistry Extreme Diversity™ platform to develop novel therapeutics for the treatment of diseases that are caused by excessive or uncontrolled activation of the complement system, which is a critical component of the body’s immune system. The Company’s lead compound, RA101495, is a self-administered subcutaneous injection that is entering Phase 2 development for the treatment of paroxysmal nocturnal hemoglobinuria, or PNH, a life-threatening blood disorder. “Listing on Nasdaq is an important milestone for our Company that we are very proud to have achieved,” said Douglas Treco, Ph.D., Chief Executive Officer and Co-Founder of Ra Pharmaceuticals Inc. “Nasdaq is home to many of the world’s most innovative biotechnology companies, and we are honored to now be among them. We look forward to executing on our clinical strategy in our quest to create novel therapies for patients and value for our shareholders.” “Ra Pharmaceuticals is developing the next generation of therapies to treat complex autoimmune diseases,” said Nelson Griggs, Executive Vice President, Listing Services, Nasdaq. “As the leading exchange for some of the world’s most successful life sciences companies, we are proud to be the listing partner of Ra Pharmaceuticals as they continue to develop therapies that will improve the lives of people with these serious and sometimes debilitating diseases.” The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. Information about the company is provided by the company or comes from the company’s public filings and is not independently verified by Nasdaq.  Neither Nasdaq nor any of its affiliates makes any recommendation to buy or sell any security or any representation about the financial condition of any company. Statements regarding Nasdaq-listed companies are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED. About Nasdaq Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,700 listed companies with a market value of approximately $9.3 trillion and more than 18,000 corporate clients. To learn more, visit: nasdaq.com/ambition or business.nasdaq.com

Loading Ra Pharmaceuticals collaborators
Loading Ra Pharmaceuticals collaborators